Business
Voyageur Pharmaceuticals Ltd. Strengthens Board of Directors with Wall Street Expertise to Facilitate U.S. Market Expansion
(TheNewswire) Calgary, AB – October 23, 2025 - TheNewswire – Voya...
About this update from Voyageur Pharmaceuticals Ltd
[{"type":"text","content":"Voyageur Pharmaceuticals Ltd. Strengthens Board of Directors with Wall Street Expertise to Facilitate U.S. Market Expansion\n\n\n (TheNewswire)\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Calgary, AB – October 23, 2025 -\n \n\n TheNewswire\n \n\n –\n \n\n Voyageur Pharmaceuticals Ltd. (TSXV: VM)\n(OTC: VYYRF),\n \n\n (the “Company” or\n“Voyageur”) a Canadian developer of pharmaceutical-grade barium\nand iodine for medical imaging contrast media, is pleased to announce,\nsubject to regulatory approval, the expansion of its board of\ndirectors and the appointment of two experienced Wall Street\nexecutives:\n \n\n\n\n\n\n Jeffrey J. Kraws, an award-winning Wall Street analyst\nand biotech strategist, and\n \n\n\n\n\n\n Christopher A. Van Buren, CFA, a seasoned financial and\nenterprise risk management executive.\n \n\n\n\n\n\n These two new directors bring invaluable expertise in\nU.S. capital markets, IPO execution, and regulatory compliance,\nstrategically positioning Voyageur for potential access to U.S.\nmarkets. This move aims to attract significant American investment to\nsupport Voyageur's growth in the diagnostic imaging\nsector.\n \n\n\n\n These new directors' proven track records in\norchestrating U.S. public offerings, capital raises, and cross-border\nlistings will be instrumental in bridging Voyageur's TSX Venture\nExchange presence to the depth and liquidity of U.S. markets.\nVoyageur’s management anticipates this will enable accelerated\ncommercialization and strategic partnerships.\n \n\n\n\n \"We believe Jeffrey and Christopher bring the\nprecise blend of Wall Street acumen and healthcare finance expertise\nneeded to help unlock U.S. capital markets for Voyageur,\" said\nBrent Willis, Voyageur’s CEO. \"Their collective experience in\nguiding biopharma and asset management firms through successful IPOs,\ndebt and equity financing, and regulatory compliance should streamline\nour path to attracting institutional U.S. investors and provide the\nfinancial resources necessary to scale our innovative pipeline for\nNorth American healthcare providers.\"\n \n\n\n\n Jeffrey J. Kraws\n \n\n , with over 35 years of experience, has led U.S. capital\nraises, IPOs, and secondary offerings for pharmaceutical and life\nsciences firms. As Chairman of Theri...